simbha

One more push above 33... Kaboom!

看多
NASDAQ:EXEL   Exelixis, Inc.
Consistently performed in FDA approvals for last 2 years.
Last push above 33 sometime this year with accelerating revenues growth... TA roadmap is set.
免責聲明

這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。